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Integrating dynamic mixed-effect modelling and penalized
regression to explore genetic association with
pharmacokinetics
Julie Bertranda, Maria De Ioriob and David J. Baldinga
Context In a previous work, we have shown that penalized
regression approaches can allow many genetic variants to
be incorporated into sophisticated pharmacokinetic (PK)
models in a way that is both computationally and
statistically efficient. The phenotypes were the individual
model parameter estimates, obtained a posteriori of the
model fit and known to be sensitive to the study design.
Objective The aim of this study was to propose an
integrated approach in which genetic effect sizes are
estimated simultaneously with the PK model parameters,
which should improve the estimate precision and reduce
sensitivity to study design.
Methods A total of 200 data sets were simulated under the
null and each of the following three alternative scenarios:
(i) a phase II study with N= 300 participants and n= 6
sampling times, wherein six unobserved causal variants
affect the drug elimination clearance; (ii) the addition of
participants with a residual concentration collected in
clinical routine (N= 300, n= 6 plus N= 700, n= 1); and
(iii) a phase II study (N= 300, n= 6) in which four
unobserved causal variants affect two different model
parameters.
Results In all scenarios the integrated approach detected
fewer false positives. In scenario (i), true-positive rates were
low and the stepwise procedure outperformed the
integrated approach. In scenario (ii), approaches performed
similarly and rates were higher. In scenario (iii), the
integrated approach outperformed the stepwise procedure.
Conclusion A PK phase II study with N= 300 lacks the
power to detect genetic effects on PK using genetic arrays.
Our approach can simultaneously analyse phase II and
clinical routine data and identify when genetic variants
affect multiple PK parameters. Pharmacogenetics and
Genomics 25:231–238 Copyright © 2015 Wolters Kluwer
Health, Inc. All rights reserved.
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Introduction
Some established drugs can show high interindividual
variability. Adverse drug reactions are an extreme con-
sequence of this variability, which account for 6.5% of
hospital admissions [1]. Ingelman-Sundberg and Gomez
[2] estimated that 10–20% of such drug reactions could
be due to genetic factors. Moreover, CYP2C9 and
VKORC1 polymorphisms have been shown to explain up
to 40% of the variability in the response to warfarin [3].
Furthermore, regulation authorities now recommend to
perform genetic association studies when a polymorphic
transporter has been shown to play a major role in the
pharmacokinetics (PK) of a drug and/or there is marked
interindividual variability or inexplicable outliers repor-
ted in phase I or subsequent studies [4]. Likewise, sev-
eral initiatives have been created to identify and control
for genetic sources of variability in drug response, such as
the recent P4Medecine [5].
However, large randomized control trials such as the
European EU-PACT [6] and the American COAG [7]
can raise inconsistent results, partly because of genetic
heterogeneity but also because they were not using the
same genetic-based dosing algorithm. Indeed, COAG
used no loading dose, so decisions were made based on
concentrations not yet at steady-state, whereas EU-
PACT used a dosing algorithm based on a nonlinear
mixed-effect (NLME) model of warfarin PK and phar-
macodynamics. One possible explanation is that doses
predicted from such a model were better tailored to
patients, which explains the EU-PACT success in
assessing the benefit of genetic-guided dosing when
COAG showed no significant differences between the
genetic-guided and standard care treatment arms.
This example provides an incentive to use NLME
models in the exploration of further genetic associations
with drug response.
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Indeed a few years ago, Lehr et al. [8] proposed a simple
but computationally intensive stepwise regression
approach to perform high throughput genetic associations
using NLME models. In a previous work, we compared
their procedure to an approach combining penalized
regression and NLME models. We showed through a
realistic simulation study that our approach was compu-
tationally and statistically efficient to analyse a large set of
single nucleotide polymorphisms (SNPs) [9]. The phe-
notypes, in both our approach and the stepwise proce-
dure, are the empirical Bayes estimates of the subject-
specific model parameters. However, the latter are
obtained a posteriori of the model fit and are known to be
sensitive to the study design.
Therefore, we propose, here, integrating penalized
regression and NLME models, in which the selection of
SNPs is simultaneous with the estimation of the model
parameters. We assessed this integrated approach
through a simulation study based on the drug metabo-
lizing enzymes and transporters (DMET) Chip [10] for
the SNP set and a moderately complex dose-
concentration model with six parameters for the drug
response. We compared its performance with the step-
wise procedure on three scenarios differing in terms of
SNP effect on PK model parameter or study design.
Methods
Nonlinear regression
To describe the time course of the drug concentration in
each participant after intake, we used a compartmental
representation of the human body. Each compartment
represented a biological unit (such as a group of organs
with similar physicochemical properties) where the drug
distributes in an homogenous fashion. The absorption
and elimination are described as first-order input and
output functions from a central unit (e.g. the systemic
circulation), and distribution to less perfused organs is
represented by additional compartments communicating
with the central unit through first-order influx and efflux.
This dynamic system can be translated in a mathematical
function nonlinear in its parameters, the absorption (ka)
and elimination (k) rates, the volumes of distribution of
the central (Vc) and peripheral (Vp) compartments and the
influx and efflux rates to a peripheral compartment
(kcp and kpc). The volumes, the elimination rate from the
central unit and the influx and efflux rates define
the time required to clear the body from the drug, as
well as the time to reach an equilibrium for a given
dosage regimen. Pharmacologists often combine those
in the elimination (Cl= k/Vc) and intercompartmental
(Q= kcp/Vc= kpc/Vp) clearances, which express the volumes
of drug cleared per time unit.
Mixed-effect framework
Each of the participants had been sampled following the
drug intake, at a number of timepoints that can differ
across individuals. The mixed-effect framework enables
a simultaneous model fit, borrowing information from
participants with several sampling times for the analysis
of participants with fewer profiles.
Let yi be the vector of concentrations of participant
i= 1, ..., N, sampled at the ni timepoints in vector ti after
intake of dose Di. f is a function that may be nonlinear in
ϕi, its parameter vector, and which specifies the con-
centration of subject i:
yi ¼ f ðfi; Di; tiÞþei
fi ¼ mþZi
Zi  N 0; Oð Þ
ei  Nð0; Inis2Þ;
ð1Þ
where ηi and εi are the vectors of random effects and
residual errors for participant i, and θ= (μ, Ω, σ) denotes
population-level model parameters for the vector of fixed
effects μ, the matrix of interindividual variance-
covariance Ω and the residual error variance σ, respec-
tively. To ensure positive concentrations, concentrations
can be modelled on the log-scale or have a proportional
residual variance at the likelihood level.
In this work, we considered the stochastic approximation
of the expectation maximization (SAEM) algorithm [11]
to obtain the model parameter estimates (see Appendix
1, Supplemental digital content 1, http://links.lww.com/
FPC/A810).
Genetic association analyses
The influence of SNPs on the PK of each individual is
incorporated in the NLME model through the addition
of a SNP-PK parameter relationship matrix Ci to Eq. (1):
fi ¼ CimþZi; ð2Þ
where Ci is a block-diagonal matrix specific to each
individual i that contains a block of SNPs under study per
PK model parameter. μ is then a stacked vector of the PK
parameter-specific regression coefficients. It contains
successively for each PK parameter (such as Cl and Vc), its
intercept and as many β as there are SNPs for that
parameter. ηi captures for each PK parameter the depar-
ture of the individual i from the population value.
Therefore, mixed effects enable to explore SNP effect
on separate PK parameters and moreover to quantify
the part of the interindividual variability explained.
However, when the number of SNPs is large or even
exceeds the number of participants, maximum likelihood
estimation can no longer be performed.
The most common method for a large number of SNPs is
the stepwise procedure. First, an NLME PK model is
fitted to the data to obtain estimates of y^. Thereafter, for
each participant i, an empirical Bayes estimate of each PK
parameter is derived using these y^ and for each PK model
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parameter d the vector f^d of size N is regressed on each
candidate SNP in a separate linear model. In a second
step, for each SNP that passes the screening step, an
NLME PK model including the SNP-PK parameter
relationship as in (2) is fitted to the data and the best
model is selected using a likelihood ratio test (LRT).
From the latter, new vectors Z^d are derived and regressed
on each candidate SNP as in step 1.
The procedure will continue until no more SNP effect is
found on PK parameters in steps 1 or 2. In genetic
association analyses, a certain amount of correlation due
to linkage disequilibrium is expected among the SNPs.
Therefore, Lehr et al. [8] proposed that, if after the first
step there are multiple significant SNPs with r2 of 0.8 or
more, only the most significant is advanced to the next
step of the analysis.
The integrated approach, that we propose, is an auto-
matic variable selection method in which we use a
penalized regression in the maximization step of μ at each
iteration k of the SAEM algorithm, considering each PK
parameter d independently:
mdkþ1 ¼ Argminmd
XN
i¼1
ðSd ;i;kCdimdkÞ2þPðmdkÞ; ð3Þ
where Sd,i,k is the sufficient statistic derived from the
stochastic approximation of the model likelihood for
updating μd (see details in Appendix 1, Supplemental
digital content 1, http://links.lww.com/FPC/A810), Cdi is the
block of SNPs under study for PK model parameter d and
P is the penalty term. Penalized regression shrinks effect
size coefficients of SNPs towards zero. We considered
two types of penalized regression: the Lasso and
HyperLasso (HLasso), a generalization of the Lasso. The
Lasso requires only one penalty term ξ; the higher this
term, the stronger the penalty and the fewer the SNPs
that enter the model:
PðmdkÞ ¼ x
X
v
bdvkj j;
where ξ is a regularization parameter and βdvk is the effect
size of SNP v on PK parameter d at iteration k. In con-
trast, HLasso requires two penalty terms: the shape γ and
the scale λ:
PðmdkÞ ¼ 
X
v
b2dvk
4g2
þ log Dð2l1Þ bdvkj jg
  
;
where D is the parabolic cylinder function. When both γ
and λ tend towards infinity, HLasso converges to the
Lasso. Here, we set γ to 1, as it has been found to perform
well [12].
For the screening step of the stepwise procedure, the
per-test type I error α was set to achieve a target family
wise error rate (FWER) using the Sidak correction:
FWER ¼ 1ð1aÞNpar , where Npar is the total number of
SNP tested on all PK model parameters. For the ensuing
LRT step, the per-test type I error was set to 1%.
For the integrated approach, we set ξ and λ using an
asymptotic approximation [13], which ensures the same
target α as the screening step of the stepwise procedure:
g 0 ðbdvk ¼ 0þÞ ¼ F1 1
a
2
  ﬃﬃﬃﬃﬃﬃ
N
s2
r
; ð4Þ
where g′ (βdvk= 0 + ) is the first derivative of the log-prior
distribution specific to the penalized regression, Φ− 1
is the inverse normal distribution function and σ* the
standard deviation of sd,i,k (see details in Appendix 2
Supplemental digital content 2, http://links.lww.com/FPC/
A811).
Simulation study
The genotypic data for each patient were simulated using
Hapgen (Wellcome Trust Centre for Human Genetics,
Oxford, UK) [14] for 1227 genetic variants from the
DMET Chip [10] located on 171 genes involved in drug
metabolism spanning the 22 autosomes and chromosome
X. The median (range) interval covered by the SNPs is
29 (0–804) kb per gene, with 6 (1–56) SNPs per gene.
Hapgen resamples known haplotypes and can thereby
produce samples with patterns of linkage disequilibrium
mimicking those in real data. The reference haplotype
set used in our simulations comes from HapMap
release 21 for the White population. Haplotypes were
paired randomly, thus imposing Hardy–Weinberg
equilibrium. SNPs were coded 0, 1, or 2 expressing the
allele dosage.
The concentration data were simulated from a two-
compartment model. The parameter values were
inspired from a real case study with non-negligible
interindividual coefficients of variation from 30 to 70%
and heteroscedastic variance for the residual errors [9].
We simulated 200 data sets per hypothesis (null
hypothesis of no SNP effect on PK model parameters, H0
and an alternative hypothesis of existing SNP effects on
PK model parameters, H1) for three different scenarios
with different study designs or SNP effects under H1.
The first scenario corresponds to a large phase II study
with N= 300 participants and n= 6 sampling times allo-
cated to ensure a reasonable precision of parameter
estimates for the basic model using the optimization
algorithm PFIM [15]. Under H1, six unobserved causal
variants decreased Cl, explaining 1, 2, 3, 5, 7 and 12% of
its interindividual variability, respectively (see Appendix
3, Supplemental digital content 3, http://links.lww.com/
FPC/A812).
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The second scenario corresponds to the combination of this
phase II study (N= 300, n= 6) with residual concentrations
collected from several participants (N= 700, n= 1).
The last scenario considers four unobserved causal var-
iants affecting two different model parameters under H1.
The first and the third causal variants decrease Cl,
whereas the second and the fourth decrease Vc.
Moreover, the first causal variant is correlated with the
second one and the third causal variant with the fourth
(r2≥ 0.5). Each causal variant explains 15% of the inter-
individual variability of its associated parameter (see
Appendix 3, Supplemental digital content 3, http://links.
lww.com/FPC/A812). The study design is the same as in
scenario 1 (i.e. N= 300, n= 6).
Evaluation
The DMET Chip mainly contains genes coding for
proteins involved in distribution or elimination processes.
Thus, in our model we explored SNP effect on Cl, Q and
Vc, which describe these processes. Vp is not considered
because it has no interindividual variability.
We specified an overall FWER of 20%, more liberal than
usual, because this allows better power comparisons for
lower-effect SNPs [9].
To be realistic, the causal variants are not observed (i.e.
not among the tested SNPs); therefore, a true positive
(TP) was defined as any significant SNP with an r2 of
0.05 or more with a causal variant. For both TP and false
positive (FP) evaluation, sets of SNPs, with each pair in
the set having an r2 of 0.8 or more, were considered as
one signal. Scenarios in which the six causal variants
affect Cl, any signal for Q or Vc is a FP, whereas in sce-
nario 3 in which two causal variants affect Cl and two
causal variants affect Vc, any signal on Q is a FP.
Counts of TP per data set were compared across methods
using the Friedman test [16] and pairwise Wilcoxon
signed-rank tests using a Holm correction [17] for mul-
tiple testing.
Furthermore, to explore the impact of the study design
on the performances of the different methods, we cal-
culated the median (range) shrinkage over the 200 data
sets (see Appendix 3, Supplemental digital content 3,
http://links.lww.com/FPC/A812). This metric quantifies
how much empirical Bayes estimates of individuals with
little information (i.e. few sampling times) are moved
towards the fixed effect (i.e. typical value). A spurious
covariate association can result from a large shrinkage –
for example, greater than 0.5 [18].
Moreover, we assessed how our modification of the
SAEM algorithm impacts the accuracy and precision of its
estimates under H0 by calculating relative estimation
errors, relative and relative root mean square errors for
each model parameter (see Appendix 3, Supplemental
digital content 3, http://links.lww.com/FPC/A812).
We used the SAEM algorithm implementation in the
SAEMIX R package [19]. Initial conditions were set to
the simulated values, as our purpose was not to challenge
the estimation algorithm itself. In the expectation phase,
the number of iterations was set to 300 for the stochastic
phase and to 100 for the cooling phase. The number of
Monte Carlo Markov chains for simulation of the indi-
vidual parameters in the E-step was set to 5. The mar-
ginal log likelihood to be used for the LRT in the
stepwise procedure was calculated using a first-order
linearization of the model around the posterior mode of
the random effects.
For the penalized regression, we used the HLasso soft-
ware (C program written by Dr Clive Hoggart, London,
UK) [13] to run both the Lasso and HLasso models,
keeping the highest mode of 10 iterations, where the order
in which the SNPs were updated was permuted to account
for the potential multimodality of the posterior density.
All analyses were run on the UCL Legion High
Performance Computing Facility on cores with 2GB
RAM. Central processing unit times are given as median
(range) on the 200 data sets.
Results
As shown in Fig. 1, we simulated profiles with large
interindividual variability. In this figure, we have high-
lighted one homozygote individual per causal variant.
One could be surprised that the PK profiles are not
superposed according to the percentage of inter-
individual variability explained. This arises both because
variance explained is a function of both effect size
and population allele frequency, and because a subject
PK profile results from the effect of multiple genetic
variants.
Table 1 contains the FWER estimates of each method
for scenario 1 and scenario 2. Scenarios 1 and 3 share the
same study design (N= 300/n= 6) and only differ in the
presence of causal variants. All FWER estimates are
within the interval 0.145–0.255, which is a 95% predic-
tion interval under H0.
Figure 2 highlights the trade-off of the three methods on
each scenario in terms of TP and FP (see Table 3 in
supplementary material for details, Supplemental digital
content 4, http://links.lww.com/FPC/A813). In scenario 1,
the TP rate was 30.5% for the stepwise approach, which
was significantly higher than the integrated approach
with Lasso (28.3%, P = 0.003) or HLasso (27.9%,
P= 0.002), but the FP count for the stepwise approach
was also significantly higher (P= 0.002 and 0.001,
respectively). In scenario 2, the increase in the sample
size despite most of the participants having only one
concentration led to a TP rate of 60% with no significant
difference across methods, but still a significantly higher
FP count for the stepwise approach compared with the
integrated approach with Lasso (P≤ 0.001 from pairwise
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Wilcoxon signed-rank test) or HLasso (P≤ 0.001) was
observed. In scenario 3, the stepwise procedure had a TP
rate of 66% versus 73 and 74% for the integrated
approach with Lasso and HLasso (P≤ 0.001 and 0.001,
respectively); there were no significant differences in
FP count.
Figure 3 displays the power estimates of all methods to
detect each of the four causal variants in scenario 2, as
well as the mean and range of shrinkage estimates for Vc,
Cl and Q. All methods were about 50% less powerful for
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Table 1 Family wise error rate (FWER in %) estimates and their
confidence intervals for the three methods on scenario 1 and/or 3
(N=300/n=6) and scenario 2 (N= 300/n= 6 and N=700/n= 1);
FWER expected value of 20% with prediction interval on 200 data
sets of 14.5–25.5%
Method Scenario 1 and/or 3 Scenario 2
Stepwise procedure 19.0 [14.2–25.0] 22.5 [17.3–28.7]
Lasso 20.0 [15.0–26.1] 21.0 [15.9–27.2]
HyperLasso 22.5 [17.3–28.7] 21.5 [16.4–27.7]
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causal variants underlying Vc compared with Cl, the drop
being greater for the stepwise approach. When con-
sidering the shrinkage on Vc and Cl, we observed that it
was notably larger on Vc, about 40%, than on Cl, less
than 5%. These results suggest that the shrinkage
lowers the power of the methods to detect a genetic
effect on a model parameter, the stepwise procedure
being more sensitive to its influence than the integrated
approaches.
Table 2 contains the mean and range runtime estimates
of all methods on all scenarios under both hypotheses.
The stepwise procedure runs up to 20 times faster than
the integrated approach under H0, but the gap is reduced
in the presence of causal variants and even reverses on
large sample size. A reduction of the runtime gain is also
observed if more than one parameter is affected by a
causal variant.
All methods performed similarly in terms of accuracy and
precision of estimation, with mean (range) relative bias of
0.01 and (− 0.05 to 0.05) for the fixed effects and − 0.001
(− 0.110 to 0.140) for the variances, and relative root
mean square errors 0.10 (0.01–0.23) for the fixed
effects and 0.21 (0.05–0.56) for the variances (see
Supplementary Figure 4, Supplemental digital content 5,
http://links.lww.com/FPC/A814).
Discussion
In this work, we propose an integrated approach to
simultaneously test for SNP effect on PK model para-
meters, and estimate effect sizes, as opposed to a step-
wise procedure, which test for SNP effect a posteriori of
the NLMEM estimation step.
Because we used Lasso-type penalization for the selec-
tion process, the integrated approach tends to be more
conservative than the stepwise procedure. Indeed, as
seen in scenario 1, the integrated approach detects sig-
nificantly less FP for a small reduction in power.
However, the integrated approach appears more powerful
when genetic variants affect multiple PK parameters.
Indeed, by accounting for the effect of SNPs on Cl during
the estimation process instead of regressing each SNP on
the empirical Bayes estimates, the integrated approach
was less sensitive to the shrinkage on Vc in scenario 3. Of
note, we see little difference using Lasso or HLasso
probably because of the SNP set not being on the
genome-wide scale. Our approach could be extended to
genome-wide genotyping data, especially using HLasso.
However, in scenario 2 (1200 SNPs and 1000 partici-
pants) on call to HLasso requires ∼ 17 s, whereas with
650k SNPs and 1000 participants, Hoffman et al. [20]
reported an average HLasso runtime of 52 min.
Moreover, this additional runtime would be multiplied
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Table 2 Median [range] computing times in hours for the three methods on each scenario under H0 and H1
Scenario 1 Scenario 2 Scenario 3
Method H0 H1 H0 H1 H1
Stepwise procedure 0.05 [0.05–0.24] 0.24 [0.06–1.09] 0.16 [0.11–0.93] 2.31 [0.31–8.53] 0.84 [0.06–2.56]
Lasso 1.04 [0.81–1.48] 1.14 [0.83–1.61] 1.79 [1.40–2.48] 1.90 [1.47–3.73] 1.51 [1.23–9.05]
HyperLasso 1.08 [0.81–1.57] 1.19 [0.84–1.60] 1.91 [1.44–3.14] 1.94 [1.58–4.19] 1.62 [0.79–1.83]
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by the number of iterations of the modified-SAEM
algorithm.
Therefore, we expect runtimes to increase dramatically.
Phase II study designs are highly variable and the sample
size can vary from tens to hundreds [21,22]. Here,
N= 300 was the largest value we considered and never-
theless found a lack of power to detect multiple realistic
and clinically relevant genetic effects on PK. With our
approach or using the stepwise procedure, the power to
detect at least three causal variants (in scenario 1 and 2) is
less than 20%. However, NLMEM can handle few and
unbalanced data and thereby can analyse combinations of
different clinical studies to increase the power to detect
covariate effects [23]; indeed we show, here, that com-
bining a large phase II study with single subject mea-
surements permits a large increase in power for both
methods equally. Being capable of the simultaneous
analysis of multiple studies with different designs, the
approach we propose can make the most out of projects
such as tranSMART [24], combining clinical and geno-
mic data collected on open-access and open-source
platforms.
One main feature of the integrated approach was that the
FWER depends on the penalty term only. For the
stepwise procedure, in contrast, it depends on the
thresholds at the screening step and the model inclusion
step, which have to be chosen based on an asymptotic
distribution (as performed here) or using permutations
[25]. Moreover, the stepwise procedure can have many
variations; the screening step can be performed using an
analysis of variance or a linear regression, whereas the
model inclusion step can be performed using criteria such
as the AIC or the BIC, a LRT (as performed here) or a
Wald test. The use of an integrated approach comes
nevertheless at a non-negligible cost in terms of runtime.
However, the runtime difference with using a stepwise
procedure diminishes with increasing sample size.
In conclusion, the integrated approach we propose seems
well suited to the analysis of large SNP sets with PK
collected across multiple clinical studies. We only con-
sidered a hypothetical two-compartment PK model in
this simulation study. However, we expect our approach
to be effective on more complex drug response models,
as the SAEM algorithm has been successfully used on
HIV viral dynamics [26] and in the hidden Markov model
of daily seizures data [27]. Our results suggest imple-
mentation of the integrated approach as an option in the
next version of SAEMIX in future studies.
At present, it does not handle nonsolvable ordinary dif-
ferential equation system, missing SNPs and interocca-
sion variability, as those features are not yet covered by
the saemix R package. In parallel of these developments,
we would like to consider alternatives such as Bayesian
variable selection methods. Indeed, the flexibility of
Bayesian modelling enables fitting complex
physiological-based models to heterogenous data [28] but
their application in pharmacogenetics, representing an
additional layer of complexity, remains to be further
explored.
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